EICHORPublic-registry site landscape for NCT07751042, “Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab”, a Advanced Solid Tumor study sponsored by Strand Therapeutics Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07751042 (registry record) |
| Study title | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab |
| Official title | A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab |
| Sponsor | Strand Therapeutics Inc. |
| Condition(s) | Advanced Solid Tumor |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 2 |
| Intervention(s) | STX-003, KEYTRUDA® |
| Site countries | United States |
At HonorHealth Research Institute — one of the facilities listed on this trial — 18 other studies are actively recruiting Advanced Solid Tumor patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07751042.
Eichor generates a preliminary site-risk snapshot for NCT07751042 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
